[1]GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet Neurol, 2024, 23(10): 973-1003.
[2]Liu J Y, Xu A X, Zhao Z F, et al. Epidemiology and future trend predictions of ischemic stroke based on the global burden of disease study 1990-2021[J]. Commun Med, 2025, 5(1): 273.
[3]Gutierrez J, Turan T N, Hoh B L, et al. Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment[J]. Lancet Neurol, 2022, 21(4): 355-368.
[4]Wang Y J, Meng X, Wang A X, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med, 2021, 385(27): 2520-2530.
[5]Gao Y, Chen W Q, Pan Y S, et al. Dual antiplatelet treatment up to 72 hours after ischemic stroke[J]. N Engl J Med, 2023, 389(26): 2413-2424.
[6]Gao P, Wang T, Wang D M, et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: the CASSISS randomized clinical trial[J]. JAMA, 2022, 328(6): 534-542.
[7]Huo X C, Ma G T, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med, 2023, 388(14): 1272-1283.
[8]Wang Y J, Jing J, Meng X, et al. The third China national stroke registry (CNSR-Ⅲ) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics[J]. Stroke Vasc Neurol, 2019, 4(3): 158-164.[9]Jin J X, Ma P Z, Wang E Y, et al. Risk factors of recurrence of acute ischemic stroke and construction of a nomogram model for predicting the recurrence risk based on lasso regression[J]. J Southern Med Univ, 2024, 44(12): 2375-2381.
[10]Wang Y J, Zhao X Q, Liu L P, et al. Outcomes of symptomatic intracranial large artery stenoses, occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) study[J]. Stroke, 2014, 45(3): 663-669.
[11]Almallouhi E, Al Kasab S, Yamada L, et al. Relationship between vascular risk factors and location of intracranial atherosclerosis in the SAMMPRIS trial[J]. J Stroke Cerebrovasc Dis, 2020, 29(5): 104713.
[12]Kwon H M, Lynn M J, Turan T N, et al. Frequency, risk factors, and outcome of coexistent small vessel disease and intracranial arterial stenosis: results from the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) trial[J]. JAMA Neurol, 2016, 73(1): 36-42.
[13]Cai J J, Chen S Z, Hu S Y, et al. Quantitative analysis of intracranial atherosclerosis and its correlation with ischemic cerebrovascular disease and prognosis[J]. Brain Sci, 2025, 15(9): 1009.
[14]Zheng W Q, Wei H, Bai F, et al. Stroke mechanism subtypes and prognosis in patients with symptomatic intracranial atherosclerosis based on multiparametric MRI[J]. J Magn Reson Imaging, 2025, 62(3): 917-927.
[15]Kelani H, Salamah H M, Berglas E, et al. Angioplasty and/or stenting after thrombectomy in patients with large vessel occlusion associated with underlying intracranial atherosclerotic stenosis: a meta-analysis and systematic review[J]. Acta Neurochir, 2025, 167(1): 274.
[16]Yao M X, Qiu D H, Zheng W C, et al. Effects of early-stage blood pressure variability on the functional outcome in acute ischemic stroke patients with symptomatic intracranial artery stenosis or occlusion receiving intravenous thrombolysis[J]. Front Neurol, 2022, 13: 823494.
[17]刘丹琪, 袁占乔, 于小舟, 等. 复发性脑梗死危险因素的研究进展[J]. 中国医学前沿杂志: 电子版, 2022, 14(2): 58-64.
[18]王辉, 王静, 汪兰. 脑小血管病总负荷评分联合磁敏感加权血管造影预测急性腔隙性脑梗死卒中复发的临床价值[J]. 全科医学临床与教育, 2024, 22(2): 123-127.
[19]Prabhakaran S, Liebeskind D S, Cotsonis G, et al. Pre-dictors of early infarct recurrence in patients with symptomatic intracranial atherosclerotic disease[J]. Stroke, 2021, 52(6): 1961-1966.
[20]Liu Y Y, Zou Y X, Zhou H Y, et al. Prognosis of incidentally detected asymptomatic intracranial atherosclerotic stenosis: a prospective hospital-based cohort study[J/OL]. Int J Stroke, 2025: 17474930251383855. (2025-09-19)[2025-10-05]. https://pubmed.ncbi.nlm.nih.gov/40973985/.
[21]Erdur H, Scheitz J F, Ebinger M, et al. In-hospital stroke recurrence and stroke after transient ischemic attack: frequency and risk factors[J]. Stroke, 2015, 46(4): 1031-1037.
[22]Bjerkreim A T, Thomassen L, Brøgger J, et al. Causes and predictors for hospital readmission after ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2015, 24(9): 2095-2101.
[23]Xu X M, Lan L F, Li Z H, et al. Associations of cerebral perfusion with infarct patterns and early neurological outcomes in symptomatic intracranial atherosclerotic stenosis[J]. Front Neurol, 2025, 16: 1551364.
[24]Zhu L, Li Z Z, Li X H, et al. Magnetic resonance-based hemodynamic model in symptomatic intracranial atherosclerotic disease[J]. World Neurosurg, 2025, 204: 124570.
[25]潘树超, 汪元浚. 炎症因子C-反应蛋白和白介素-6在缺血性脑卒中的研究进展[J]. 临床医学进展, 2023, 13(1): 232-237.
[26]Libby P. Inflammation and the pathogenesis of atherosclerosis[J]. Vascul Pharmacol, 2024, 154: 107255.
[27]Ajoolabady A, Pratico D, Lin L, et al. Inflammation in atherosclerosis: pathophysiology and mechanisms[J]. Cell Death Dis, 2024, 15(11): 817.
[28]Jing J, Liu Z Y, Guan H, et al. A deep learning system to predict recurrence and disability outcomes in patients with transient ischemic attack or ischemic stroke[J]. Adv Intell Syst, 2023, 5(4): 2200240.
|